Taysha Gene Therapies Stock (NASDAQ:TSHA)
Previous Close
$2.28
52W Range
$1.19 - $4.32
50D Avg
$1.98
200D Avg
$2.40
Market Cap
$434.48M
Avg Vol (3M)
$2.96M
Beta
0.41
Div Yield
-
TSHA Company Profile
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
TSHA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AKRO | Akero Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| GOSS | Gossamer Bio, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| LRMR | Larimar Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| BMEA | Biomea Fusion, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| ALEC | Alector, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| CABA | Cabaletta Bio, Inc. |
| INZY | Inozyme Pharma, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| FIXX | Q32 Bio Inc. |
| STTK | Shattuck Labs, Inc. |
| ELYM | Eliem Therapeutics, Inc. |